Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 663 (LINC00663) is a human long non-coding RNA gene that does not encode a protein product. It is primarily localized in the nucleus and functions as a gene regulator, partly through interacting with transcription factors such as EBF1 to upregulate other genes like NR2F1. LINC00663 is overexpressed in various cancers, including bladder, pancreatic, and glioma, where it fosters cell proliferation, inflammation, and angiogenesis. Loss of LINC00663 suppresses tumor growth and inflammatory signaling in preclinical studies. While not a classical therapeutic target, it is of increasing interest for its roles in oncogenesis and as a potential cancer biomarker.
Not applicable for drugs, as there are no known drugs targeting this lncRNA. Mechanistically, LINC00663 acts by scaffolding transcription factors (e.g., EBF1) to gene promoters (e.g., NR2F1), thereby regulating the expression of downstream genes involved in cancer development and inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 663 (LINC00663).